| News

Pharmaceutical industry is driving the Swiss economy

22.11.2017

The number of jobs in the pharmaceutical industry is on a steady rise – and other industries are benefiting from the success of the pharmaceutical companies. According to a new study from BAK Economics, the pharmaceutical industry is the most important driver of growth in Switzerland as a centre of industry.

(img: Bürogebäude Bau 1/Roche)

The number of jobs in the pharmaceutical industry has increased by 12,000 positions in the past ten years. In 2016, Swiss pharmaceutical companies offered around 43,000 full-time jobs, with each job in the pharmaceutical industry generating around four times more added value as the overall economic average. These figures come from a new study from the independent economic research institute BAK Economics and the consulting firm Polynomics on behalf of the association Interpharma.

According to the study, other industries are also benefiting from the successful economic activities of the pharmaceutical industry. Calculations show that every franc of added value from the pharmaceutical industry is worth an additional 70 rappen of added value in other industries as a result of supplier orders. This results in a direct added value contribution of 49.6 billion Swiss francs, or just under 8 per cent of the economy’s total gross added value. In addition, each additional job in the pharmaceutical industry creates an additional 3.2 full-time jobs in companies in other industries.

Overall, the pharmaceutical industry is the most important driver of growth in Switzerland as a centre of industry, finds the study. Around one-fifth of Switzerland’s real economic growth came from the Swiss pharmaceutical industry.

The success of the pharmaceutical industry is partly due to the attractive conditions in which it operates in Switzerland. For large pharmaceutical companies, this includes unbureaucratic access to important export markets, the availability of qualified staff, competitive corporate taxation, as well as the fact that the excellence of Switzerland as a centre of research is ensured.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
Startups from the Basel Area ranked among the best
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Startups from the Basel Area ranked among the best

Startups from the Basel Area have been ranked highly in the TOP 100 Swiss Startup Award by Venturelab. The medtech...

Read More
Roche testing for coronavirus and flu simultaneously
Basel Area Business & Innovation, Innovation, Invest

Roche testing for coronavirus and flu simultaneously

The U.S. Food and Drug Administration has given the Basel-based life sciences company Roche authorization to use a test that...

Read More
Hengrui Medicine sets up clinical research and development in Basel
Basel Area Business & Innovation, Innovation, Invest

Hengrui Medicine sets up clinical research and development in Basel

The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research...

Read More
Polyphor awarded exclusive licensing agreement for China
Basel Area Business & Innovation, Innovation, Invest

Polyphor awarded exclusive licensing agreement for China

The Basel Area-based company Polyphor has signed an exclusive licensing agreement with Fosun Pharma in China. Fosun Pharma will lead...

Read More
New label guarantees that data remains in Switzerland
Basel Area Business & Innovation, Innovation, Invest

New label guarantees that data remains in Switzerland

With the new “swiss hosting” label, the Basel-based company swiss made software Gmbh is guaranteeing that data will not be...

Read More
Coworking in the Basel Area – An Interview with Karin Crisanto
Basel Area Business & Innovation, Switzerland Innovation Park

Coworking in the Basel Area – An Interview with Karin Crisanto

Karin Crisanto recently joined Basel Area Business & Innovation as Head of Innovation Space and Infrastructure. She previously worked for...

Read More
Switzerland ranked in second place globally
Basel Area Business & Innovation, Invest

Switzerland ranked in second place globally

The chemical and pharmaceutical industry of Switzerland has been ranked number two in the world after the USA in terms...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.